XLO — Xilio Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $49.21m
- -$88.32m
- $43.77m
Annual cashflow statement for Xilio Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -75.8 | -88.2 | -76.4 | -58.2 | -35 |
| Depreciation | |||||
| Non-Cash Items | 5.35 | 8.65 | 7.54 | 6.44 | 3.38 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -11.8 | 2 | -1.66 | 31.8 | 25.1 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -80.8 | -75.7 | -68.6 | -18.4 | -4.99 |
| Capital Expenditures | -1.1 | -1.87 | -0.486 | -0.036 | -0.518 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -1.1 | -1.87 | -0.486 | -0.036 | -0.518 |
| Financing Cash Flow Items | -0.75 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 261 | -0.069 | -6.55 | 29.2 | 87.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 179 | -77.7 | -75.7 | 10.8 | 82.3 |